Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
天大藥業:2023年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
TIANDA PHARMA To Go Ex-Dividend On June 13th, 2024 With 0.0026 HKD Dividend Per Share
April 10th - $TIANDA PHARMA(00455.HK)$ is trading ex-dividend on June 13th, 2024. Shareholders of record on June 14th, 2024 will receive 0.0026 HKD dividend per share on June 28th, 2024. The ex-di
Tianda Pharmaceutical (00455.HK) will pay a final dividend of HK0.26 cents per share on June 28
Tianda Pharmaceutical (00455.HK) announced that it intends to pay a final dividend of HK0.26 cents per share for the year ended December 31, 2023. The proposed final dividend will be paid on June 28, 2024 (Friday) after shareholders' approval at the annual shareholders' meeting.
TIANDA PHARMA: FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2023 CLOSURES OF REGISTER OF MEMBERS
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Loss attributable to shareholders of Tianda Pharmaceutical (00455.HK)'s parent company narrowed year-on-year to HK$24.2 million in 2023
Gelonghui, March 26 | Tianda Pharmaceutical (00455.HK) announced that in 2023, against the backdrop of a marked decline in the global COVID-19 epidemic and the steady recovery of the Chinese economy, the Group will continue to improve the operation and management of the three major business segments of pharmaceuticals and medical technology, traditional Chinese medicine, medical and health services through a series of measures such as consolidating core products, enriching product pipelines, expanding sales channels, and deepening the layout of the traditional Chinese medicine industry chain. The Group's annual revenue increased steadily, operating efficiency continued to improve, recorded losses narrowed significantly, and fundamentals were further improved. Total revenue of HK$532.1 million was recorded for the year (previous financial period)
Tianda Pharmaceutical (00455) announced annual results. The loss attributable to shareholders of HK$24.155 million decreased by 41.05% year-on-year
According to the Zhitong Finance App, Tianda Pharmaceutical (00455) announced its annual results for the year ended December 31, 2023. The group obtained revenue of HK$532 million, an increase of 29.77% year on year; loss due to shareholders of the parent company was HK$24.155 million, a decrease of 41.05% year on year; loss per share was 1.12 HK cents, and a final dividend of HK 0.26 cents per share was planned. In the pharmaceutical and medical technology business, benefiting from strong sales growth of the pediatric drug tonibuprofen and the maintenance of ideal sales performance for other major products, this year's revenue was HK$470.7 million (previous financial period: 3.45)
Tianda Pharmaceutical (00455) plans to pay a final dividend of HK$0.0026 per share
Tianda Pharmaceutical (00455) announced that it intends to distribute final shares for the year ended December 31, 2023...
TIANDA PHARMA: FINAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Tianda Pharmaceutical (00455) expects losses in 2023 to be reduced by more than HK$15 million compared to the previous period
Tianda Pharmaceutical (00455) announced that the company's fiscal year settlement date has been changed from March 31 to December 3...
TIANDA PHARMA: PROFIT ALERT - REDUCTION IN LOSS
Tianda Pharmaceutical (00455.HK) plans to hold a board meeting on March 26 to approve the annual results
Gelonghui March 14 | Tianda Pharmaceutical (00455.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023.
TIANDA PHARMA: DATE OF BOARD MEETING
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
No Data